The Epidemiology of urinary tract infections in HIV positive patients at a tertiary care University hospital in Central Europe (2011 - 2016).

Related Articles

The Epidemiology of urinary tract infections in HIV positive patients at a tertiary care University hospital in Central Europe (2011 - 2016).

Infect Disord Drug Targets. 2018 Apr 05;:

Authors: Klasinc R, Rieger A, Presterl E, Wrba T, Diab-Elschahawi M

Abstract
OBJECTIVES: There is limited published data concerning recent epidemiology of urinary tract infections (UTI) in HIV-patients, thus we analysed independent risk factors for UTI in HIV positive individuals and antimicrobial resistance rates of E. coli to antimicrobial agents commonly used in UTI. To determine the prevalence of symptomatic urinary tract infections (UTI) in HIV-patients we performed a retrospective case-control study.
METHODS: We included 313 HIV-patients, 101 with UTI and 212 age and gender matched controls, attending the HIV outpatient clinic at the Vienna University hospital (VUH) over a period from January 2011 to September 2016. The patients' specific data was gathered from the electronic database of the VUH. The statistical analysis was performed using SPSS Software Version 20.0.
RESULTS: HIV infected individuals with CD4 count >200 cells/mm3 were less likely than HIV infected individuals with CD4 count <200 cells/mm3 to experience UTI (OR 0.811, 95% CI 0.712-0.923 vs. OR 2.555, 95% CI 1.553 - 4.205, respectively). The in vitro resistance rate of E. coli to antimicrobial agents was as follows: ciprofloxacin (41%), mecillinam (20.5%), trimethoprim (61%), ampicillin (67%), ampicillin/ clavulanic acid (23%), cefuroxime (17%), nitrofurantoin (2%), amikacin (0%), gentamicin (9.5%).
CONCLUSIONS: Immunological status (CD4 count) is an important parameter for risk assessment of UTIs in HIV-patients. The increased resistance rate of E. coli to commonly used antimicrobial agents needs to be considered when it comes to the management of UTI, additionally surveillance strategies should be implemented in HIV-patients.

PMID: 29621966 [PubMed - as supplied by publisher]

https://ift.tt/2JqUD8Z